BA
EIGR

BlackRock Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

BlackRock Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$29K Sell
82
-16
-16% -$5.86K ﹤0.01% 3380
2016
Q3 		$40K Buy
98
+57
+139% +$29.1K ﹤0.01% 3316
2016
Q2 		$24K Buy
41
+31
+310% +$18.8K ﹤0.01% 3407
2016
Q1 		$5K Hold
10
– – ﹤0.01% 3670
2015
Q4 		$7K Hold
10
– – ﹤0.01% 3683
2015
Q3 		$5K Hold
10
– – ﹤0.01% 3705
2015
Q2 		$6K Sell
10
-99
-91% -$274K ﹤0.01% 3656
2015
Q1 		$932K Buy
109
+107
+5,350% +$935K ﹤0.01% 1606
2014
Q4 		$18K Buy
+2
New +$11.6K ﹤0.01% 3533
2014
Q3 		– Sell
-12
Closed -$85K – 3731
2014
Q2 		$85K Buy
12
+10
+500% +$50K ﹤0.01% 3126
2014
Q1 		$11K Buy
+2
New +$9.45K ﹤0.01% 3531

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors's EIGR Position: Q4 2016 in Review

BlackRock Advisors reduced its Eiger BioPharmaceuticals, Inc. (EIGR) stake by 16% in Q4 2016, selling an estimated $5.86K and leaving 82 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #3380.

BlackRock Advisors first reported a position in EIGR in Q1 2014 and has held it in 11 quarters since. The position peaked at $932K in Q1 2015. 51 funds tracked by Wall St. Rank hold EIGR as of Q4 2016.

  • BlackRock Advisors held 82 shares of Eiger BioPharmaceuticals, Inc. worth $29K as of Q4 2016.
  • BlackRock Advisors sold 16 Eiger BioPharmaceuticals, Inc. shares in Q4 2016, an estimated $5.86K.
  • Eiger BioPharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3380 holding.
  • BlackRock Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and has held it in 11 quarters since.
  • BlackRock Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $932K in Q1 2015.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.